Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Some Thoughts in Summary
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(113)
•••
Comment by prophetoffactzon Dec 23, 2022 3:45pm
84 Views
Post# 35190311

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

.

Rathjen publically set Lysosomal Storage Disorders, inflammation, and neurodegeneraion as BTI's strategic focus publically. This wasn't hidden. Herceptin was too costly. The Chiesi deal was signed. It wasn't hidden. This new strategic path takes time to develop. We are 2 1/2 years after the Chiesi signing and nothing yet; but it appears moving forward. A deal for Gaucher's has been researched with Oxyrane. but that is only 1 1/2 years old. Hunter data appears ready in Q2 2023 after Hunter became BTI's lead asset. Rathjen's strategic focus has been advanced. The Cresence deal was also executed and can be expanded with xB3 as was noted into MS which is neurodegeneration. Cresense also added clinical stage assets which Rathjen thought could get BTI to NASDAQ but the biotech market didn't bite during its historic bust. Rathjen has been trying to respond again. BTI has been living off debt and waiver extensions with Lind breathing down her back. Not much could get done with no money. Now the deal with BTI which merges with a company bigger than Cresence with clinical asssets one of which has a $5 billion market. With BTI, Cresence, and Midaetch Rathjen hopes she has an answer to the difficult market that can place xB3 in the best position ever.  
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities